SI2877460T1 - Kristalinični kompleks 1-ciano-2-(4-ciklopropil-benzil)-4- (beta-D-glukopiranoz-1-il)-benzena, postopki za njegovo pripravo in njegova uporaba za pripravo zdravil - Google Patents

Kristalinični kompleks 1-ciano-2-(4-ciklopropil-benzil)-4- (beta-D-glukopiranoz-1-il)-benzena, postopki za njegovo pripravo in njegova uporaba za pripravo zdravil

Info

Publication number
SI2877460T1
SI2877460T1 SI201331237T SI201331237T SI2877460T1 SI 2877460 T1 SI2877460 T1 SI 2877460T1 SI 201331237 T SI201331237 T SI 201331237T SI 201331237 T SI201331237 T SI 201331237T SI 2877460 T1 SI2877460 T1 SI 2877460T1
Authority
SI
Slovenia
Prior art keywords
glucopyranos
cyclopropyl
cyano
benzyl
benzene
Prior art date
Application number
SI201331237T
Other languages
English (en)
Slovenian (sl)
Inventor
Matthias Eckhardt
Tanja Butz
Frank Himmelsbach
Hans-Juergen Martin
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of SI2877460T1 publication Critical patent/SI2877460T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201331237T 2012-07-26 2013-07-25 Kristalinični kompleks 1-ciano-2-(4-ciklopropil-benzil)-4- (beta-D-glukopiranoz-1-il)-benzena, postopki za njegovo pripravo in njegova uporaba za pripravo zdravil SI2877460T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26
PCT/EP2013/065736 WO2014016381A1 (en) 2012-07-26 2013-07-25 CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
EP13740309.3A EP2877460B1 (en) 2012-07-26 2013-07-25 CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS

Publications (1)

Publication Number Publication Date
SI2877460T1 true SI2877460T1 (sl) 2018-12-31

Family

ID=48874313

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331237T SI2877460T1 (sl) 2012-07-26 2013-07-25 Kristalinični kompleks 1-ciano-2-(4-ciklopropil-benzil)-4- (beta-D-glukopiranoz-1-il)-benzena, postopki za njegovo pripravo in njegova uporaba za pripravo zdravil
SI201332031T SI3351539T1 (sl) 2012-07-26 2013-07-25 Kristalinični monohidratni kompleks 1-ciano-2-(4-ciklopropil- benzil)-4- (beta-d-glukopiranos-1-il)-benzena in L-prolina v kristalni vodi (1:1:1), postopki za njegovo pripravo in njegova uporaba kot inhibitor SGLT

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201332031T SI3351539T1 (sl) 2012-07-26 2013-07-25 Kristalinični monohidratni kompleks 1-ciano-2-(4-ciklopropil- benzil)-4- (beta-d-glukopiranos-1-il)-benzena in L-prolina v kristalni vodi (1:1:1), postopki za njegovo pripravo in njegova uporaba kot inhibitor SGLT

Country Status (23)

Country Link
US (1) US9145434B2 (cg-RX-API-DMAC7.html)
EP (3) EP2877460B1 (cg-RX-API-DMAC7.html)
JP (2) JP6538556B2 (cg-RX-API-DMAC7.html)
CN (2) CN104470908A (cg-RX-API-DMAC7.html)
AR (1) AR091908A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013294947B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015001327B1 (cg-RX-API-DMAC7.html)
CA (1) CA2878698C (cg-RX-API-DMAC7.html)
DK (2) DK3351539T3 (cg-RX-API-DMAC7.html)
EA (2) EA201600506A1 (cg-RX-API-DMAC7.html)
ES (2) ES2937665T3 (cg-RX-API-DMAC7.html)
FI (1) FI3351539T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20230081T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061450T2 (cg-RX-API-DMAC7.html)
LT (1) LT3351539T (cg-RX-API-DMAC7.html)
MX (1) MX357906B (cg-RX-API-DMAC7.html)
PL (2) PL2877460T3 (cg-RX-API-DMAC7.html)
PT (2) PT2877460T (cg-RX-API-DMAC7.html)
RS (1) RS63881B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201500574QA (cg-RX-API-DMAC7.html)
SI (2) SI2877460T1 (cg-RX-API-DMAC7.html)
TW (1) TW201418275A (cg-RX-API-DMAC7.html)
WO (1) WO2014016381A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
ES2859905T3 (es) 2013-12-17 2021-10-04 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
US10603300B2 (en) * 2014-01-23 2020-03-31 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
ES2811261T3 (es) * 2014-04-01 2021-03-11 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales equinos
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
ES2991763T3 (es) 2014-09-25 2024-12-04 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de combinación de inhibidores de SGLT2 y agonistas de dopamina para la prevención de trastornos metabólicos en animales equinos
PT3202772T (pt) * 2014-09-30 2020-11-20 Jiangsu Hengrui Medicine Co Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
CN107995862B8 (zh) 2015-08-27 2021-12-03 勃林格殷格翰维特梅迪卡有限公司 包含sglt-2抑制剂之液态药物组合物
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
KR102226465B1 (ko) * 2016-05-28 2021-03-11 하이난 수안주 파마 코포레이션 리미티드 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형
CN111511725B (zh) * 2017-12-19 2024-04-09 勃林格殷格翰维特梅迪卡有限公司 1-氰基-2-(4-环丙基-苄基)-4-(β-D-吡喃葡萄糖-1-基)-苯、L-脯氨酸和水的1:1:1共晶体的合成
UY38969A (es) 2019-11-28 2021-05-31 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
CA3223537A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び/又は治療のためのsglt-2阻害剤の使用
JP2025516857A (ja) 2022-05-25 2025-05-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Sglt-2阻害薬を含む水性医薬組成物
AU2024233233A1 (en) 2023-03-06 2025-09-11 Boehringer Ingelheim Vetmedica Gmbh Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
WO2024223388A1 (en) 2023-04-24 2024-10-31 Boehringer Ingelheim Vetmedica Gmbh Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments
TW202508593A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1581543A4 (en) * 2003-01-03 2008-03-19 Bristol Myers Squibb Co METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS
CN103435581B (zh) * 2004-03-16 2015-08-19 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
ATE491700T1 (de) * 2005-09-08 2011-01-15 Boehringer Ingelheim Int KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-
ATE517099T1 (de) * 2006-02-15 2011-08-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
EP2147008A2 (en) * 2007-05-18 2010-01-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
CN103319445B (zh) * 2007-12-27 2016-01-20 阿斯利康公司 Sglt2抑制剂的晶体结构及其制备方法
CN102177147A (zh) * 2008-08-22 2011-09-07 泰拉科斯有限公司 制备sglt2抑制剂的方法
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych

Also Published As

Publication number Publication date
WO2014016381A1 (en) 2014-01-30
ES2937665T3 (es) 2023-03-30
US20140031540A1 (en) 2014-01-30
US9145434B2 (en) 2015-09-29
JP2015522644A (ja) 2015-08-06
CN108774200A (zh) 2018-11-09
CA2878698A1 (en) 2014-01-30
MX2015000962A (es) 2015-04-16
MX357906B (es) 2018-07-30
RS63881B1 (sr) 2023-02-28
AR091908A1 (es) 2015-03-11
AU2013294947A1 (en) 2015-01-22
LT3351539T (lt) 2023-02-10
BR112015001327A2 (pt) 2017-07-04
DK3351539T3 (da) 2023-01-30
CA2878698C (en) 2021-03-23
PL3351539T3 (pl) 2023-03-06
JP2018135384A (ja) 2018-08-30
FI3351539T3 (fi) 2023-02-19
HRP20181972T1 (hr) 2019-01-25
EA201500038A1 (ru) 2015-07-30
ES2694675T3 (es) 2018-12-26
PT3351539T (pt) 2023-01-17
EA025438B1 (ru) 2016-12-30
TW201418275A (zh) 2014-05-16
PT2877460T (pt) 2018-12-19
EP3351539B1 (en) 2022-11-09
PL2877460T3 (pl) 2019-04-30
BR112015001327B1 (pt) 2022-08-16
AU2013294947B2 (en) 2017-03-30
EP3351539A1 (en) 2018-07-25
EP4166548A1 (en) 2023-04-19
HRP20230081T1 (hr) 2023-03-17
SG11201500574QA (en) 2015-02-27
JP6538556B2 (ja) 2019-07-03
EA201600506A1 (ru) 2017-03-31
SI3351539T1 (sl) 2023-03-31
EP2877460B1 (en) 2018-09-12
DK2877460T3 (en) 2019-01-07
HUE061450T2 (hu) 2023-07-28
EP2877460A1 (en) 2015-06-03
CN104470908A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
SG11201500574QA (en) CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
IL231386A0 (en) Pyrazoloquinolinone derivatives, their preparation and medical use
IL231382A (en) History of benzonitrile, their preparation and medications containing them
SI2930169T1 (sl) Kristalna oblika hidamida, pripravljalni postopek in njena uporaba
PT2687539T (pt) Variante de anexina v sua preparação e utilização
EP2933250A4 (en) PHENYL-C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF
IL233602A0 (en) History of benzamide, their preparation and pharmaceutical preparations containing them
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
IL233238A (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
PT2870145T (pt) Derivados de indeno, sua preparação e utilização como medicamentos
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF
ZA201501597B (en) Macrolide derivatives,preparation thereof and therapeutic use thereof
ZA201407214B (en) Therapeutic preparation and process for preparing said therapeutic preparation
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
GB201112642D0 (en) Surgical hair preparation substance
PL396025A1 (pl) Nowy 7-siarczan 8-prenylonaringeniny i sposób jego wytwarzania
HK1195303A (en) Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
AP2015008270A0 (en) Preparation for the treatment of tuberculosis